Gene Writing™ could lead to a cure for all manner of genetic disorders, including those that are rare and currently untreatable with existing genetic technologies. The company’s technology can change base pairs, make small insertions or deletions, and integrate entire genes into the genome. As the technology supports the design and testing of numerous natural and synthetic MGEs, Gene Writing™ is perceived to be more accurate and efficient than the existing gene correction techniques using CRISPR/Cas9 2.īy targeting DNA, the code of life and cause of genetic diseases, Gene Writing™ can write into or rewrite the genome to treat health conditions at their source. Tessera is known for its next-generation gene correction technology platform called Gene Writing™, which utilizes Mobile Genetic Elements (MGEs) 1 to overcome the limitations of existing technology. Tessera recently secured $300 million in a Series C financing, the fourth stage of startup financing that focuses on scaling successful companies, where Hanwha Impact participated as an investor. The company was founded in 2018 by Flagship Pioneering, the investor behind COVID-19 vaccine maker Moderna. Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the. For more information about Tessera, please visit . SOMERVILLE, Mass., (GLOBE NEWSWIRE) - Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today presented progress across multiple platforms and preclinical programs including increased efficiency in correcting the SCD mutation in preclinical models, increased effici. Tessera Therapeutics has tapped Liang as its first CFO, in addition to several other new hires including Mana Therapeutics vet Madhusudan Peshwa as CTO for cell therapy Avrobio alum Bill. Hanwha Impact recently announced its investment in Tessera Therapeutics, an American life sciences company that is pioneering a new category of genome engineering technology and establishing a new field of genetic medicine. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
0 Comments
Leave a Reply. |